[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 63, "title": "CEO & Vice Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 994800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Shin J.D., M.B.A.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 406256, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan E. Anderman J.D.", "title": "Senior VP, General Counsel & Corporate Secretary", "fiscalYear": 2024, "totalPay": 541620, "exercisedValue": 0, "unexercisedValue": 6250}, {"maxAge": 1, "name": "Mr. Neil L. Lerner CPA", "age": 57, "title": "Senior VP & Chief Accounting Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 61, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "Senior VP & Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.72, "open": 3.72, "dayLow": 3.63, "dayHigh": 3.84, "regularMarketPreviousClose": 3.72, "regularMarketOpen": 3.72, "regularMarketDayLow": 3.63, "regularMarketDayHigh": 3.84, "payoutRatio": 0.0, "beta": 1.296, "forwardPE": -7.3333335, "volume": 2251944, "regularMarketVolume": 2251524, "averageVolume": 1566637, "averageVolume10days": 1844090, "averageDailyVolume10Day": 1844090, "bid": 3.71, "ask": 3.74, "bidSize": 14, "askSize": 1, "marketCap": 641681152, "fiftyTwoWeekLow": 1.27, "fiftyTwoWeekHigh": 4.86, "allTimeHigh": 11.0, "allTimeLow": 0.765, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 3.704, "twoHundredDayAverage": 2.826675, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 426131552, "profitMargins": 0.0, "floatShares": 97028680, "sharesOutstanding": 171572498, "sharesShort": 15358838, "sharesShortPriorMonth": 12141511, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.089499995, "heldPercentInsiders": 0.11415, "heldPercentInstitutions": 0.67616, "shortRatio": 8.58, "shortPercentOfFloat": 0.1445, "impliedSharesOutstanding": 171572498, "bookValue": 0.674, "priceToBook": 5.548961, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -62026000, "trailingEps": -0.45, "forwardEps": -0.51, "enterpriseToEbitda": -6.33, "52WeekChange": 1.2, "SandP52WeekChange": 0.19736934, "quoteType": "EQUITY", "currentPrice": 3.74, "targetHighPrice": 32.0, "targetLowPrice": 7.0, "targetMeanPrice": 12.90909, "targetMedianPrice": 10.0, "recommendationMean": 1.27273, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 100949000, "totalCashPerShare": 0.73, "ebitda": -67320000, "totalDebt": 9904000, "quickRatio": 7.285, "currentRatio": 7.663, "totalRevenue": 0, "debtToEquity": 10.626, "revenuePerShare": 0.0, "returnOnAssets": -0.31142, "returnOnEquity": -0.51837003, "grossProfits": 0, "freeCashflow": -23926876, "operatingCashflow": -45253000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "CMPX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "earningsTimestampEnd": 1762864200, "earningsCallTimestampStart": 1754913600, "earningsCallTimestampEnd": 1754913600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.45, "epsForward": -0.51, "epsCurrentYear": -0.51875, "priceEpsCurrentYear": -7.2096386, "fiftyDayAverageChange": 0.036000013, "fiftyDayAverageChangePercent": 0.0097192265, "twoHundredDayAverageChange": 0.9133251, "twoHundredDayAverageChangePercent": 0.32310933, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-11-02", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "postMarketChangePercent": 2.6737943, "postMarketPrice": 3.84, "postMarketChange": 0.099999905, "regularMarketChange": 0.02, "regularMarketDayRange": "3.63 - 3.84", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1566637, "fiftyTwoWeekLowChange": 2.47, "fiftyTwoWeekLowChangePercent": 1.9448819, "fiftyTwoWeekRange": "1.27 - 4.86", "fiftyTwoWeekHighChange": -1.1200001, "fiftyTwoWeekHighChangePercent": -0.2304527, "fiftyTwoWeekChangePercent": 120.00001, "earningsTimestamp": 1754884800, "earningsTimestampStart": 1762864200, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1617629400000, "corporateActions": [], "postMarketTime": 1761949993, "regularMarketTime": 1761940801, "exchange": "NCM", "messageBoardId": "finmb_266166780", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.537634, "regularMarketPrice": 3.74, "displayName": "Compass Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-01"}]